Challenges in the development of high protein concentration formulations

Journal of Pharmaceutical Sciences

Volumn 93, Issue 6, 2004, Pages 1390-1402

  Shire, Steven J ^a   Shahrokh, Zahra ^b   Liu, Jun ^a  

^a GENENTECH INC   (United States)

^b Shire Canada   (Canada)

Author keywords

Analytical; High concentration; Manufacturing; Pharmaceutical; Protein formulation; Viscosity

Indexed keywords

PROTEIN; RITUXIMAB; TRASTUZUMAB;

CHROMATOGRAPHY; CONCENTRATION RESPONSE; COVALENT BOND; DEGRADATION KINETICS; DILUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG STABILITY; ELECTROPHORESIS; FILTRATION; HUMAN; MOLECULAR WEIGHT; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN INTERACTION; SHORT SURVEY; SOLUBILITY; SURFACE PROPERTY; VISCOSITY;

EID: 2642550862     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20079     Document Type: Short Survey

References (71)

1. Arakawa T, Timasheff SN. 1985. Theory of protein solubility. Methods Enzymol 114:49-77.
2. Middaugh CR, Volkin DB. 1992. Protein solubility. In: Ahern TJ, Manning MC, editors. Stability of protein pharmaceuticals, 1st edn., New York: Plenum Press. p 109-134.
3. Schein CH. 1990. Solubility as a function of protein structure and solvent components. BioTechnol 8(4):308-317.
4. Melander W, Horvath C. 1977. Salt effect on hydrophobic interactions in precipitation and chromatography of proteins: An interpretation of the lyotropic series. Arch Biochem Biophys 183(1):200-215.
5. Jenkins WT. 1998. Three solutions of the protein solubility problem. Protein Sci 7(2):376-382.
6. Leavis PC, Rothstein F. 1974. The solubility of fibrinogen in dilute salt solutions. Arch Biochem Biophys 161(2):671-682.
7. Zhang R, Hjerten S. 1997. A micromethod for concentration and desalting utilizing a hollow fiber with special reference to capillary electrophoresis. Anal Chem 69(8):1585-1592.
8. Saul A, Don M. 1984. A rapid method of concentrating proteins in small volumes with high recovery using Sephadex G-25. Anal Biochem 138(2):451-453.
9. Bull HB. 1971. An introduction to physical biochemistry, 2nd edn., Philadelphia: F.A. David Company. p 174.
10. Rothstein F. 1994. Differential precipitation of proteins. Science and technology. Bioprocess Technol 18:115-208.
11. Tanabe S, Tesaki S, Watanabe M. 2000. Producing a low ovomucoid egg white preparation by precipitation with aqueous ethanol. Biosc Biotechnol Biochem 64(9):2005-2007.
12. Glatz CE. 1992. Modeling of aggregation-precipitation phenomena. In: Ahern TJ, Manning MC, editors. Stability of protein pharmaceuticals, 1st edn., New York: Plenum Press. p 135-166.
13. Moshashaee S, Bisrat M, Forbes RT, Quinn EA, Nyqvist H, York P. 2003. Supercritical fluid processing of proteins: Lysozyme precipitation from aqueous solution. J Pharm Pharmacol 55(2): 185-192.
14. Winters MA, Knutson BL, Debenedetti PG, Sparks HG, Przybycien TM, Stevenson CL, Prestrelski SJ. 1996. Precipitation of proteins in supercritical carbon dioxide. J Pharm Sci 85(6):586-594.
15. Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. 2002. Freezing bulk-scale biopharmaceuticals using common techniques-And the magnitude of freeze-concentration. Biopharm 15(5):2-8.
16. Ahern TJ, Manning MC, editors. 1992. Stability of protein pharmaceuticals. Part A: Chemical and physical pathways of protein degradation, 1st edn., New York: Plenum Press. p 434.
17. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6(11):903-918.
18. Cleland JL, Powell MF, Shire SJ. 1993. The development of stable protein formulations: A close look at protein aggregation, deamidation and oxidation. Crit Rev Ther Drug Carrier Syst 10(4):307-377.
19. Chi EY, Krishnan S, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanism and driving forces in non-native protein aggregation. Pharm Res 20(9):1325-1336.
20. Treuheit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19(4):511-516.
21. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14(10):1472-1478.
22. Koren E, Zuckerman LA, Mire-Sluis AR. 2002. Immune responses to therapeutic proteins in humans-Clinical significance, assessment and prediction. Curr Pharm Biotechnol 3(4):349-360.
23. Minton AP. 1992. Confinement as a determinant of macromolecular structure and reactivity. Biophysical J 63(4):1090-1100.
24. Wilf J, Minton AP. 1981. Evidence for protein self-association induced by excluded volume. Myoglobin in the presence of globular proteins. Biochimica et Biophysica Acta 670(3):316-322.
25. Zimmerman SB, Minton AP. 1993. Macromolecular crowding: Biochemical, biophysical, and physiological consequences. Annu Rev Biophys Biomol Struct 22:27-65.
26. Cantor CR, Schimmel PR. 1980. Biophysical chemistry part II: Techniques for the study of biological structure and function, 1st edn., San Francisco: W.H. Freeman & Company. p 503.
27. Arakawa T, Timasheff SN. 1982. Stabilization of protein structure by sugars. Biochemistry 21:6536-6544.
28. Arakawa T, Kita Y, Carpenter JF. 1991. Protein-solvent interactions in pharmaceutical formulations. Pharm Res 8(3):285-291.
29. Pikal MJ. 1994. Freeze-drying of proteins: Process, formulation and stability. In: Cleland JL, Langer R, editors. Formulation and delivery of proteins and peptides, 1st edn., Washington D.C.: American Chemical Society. p 120-133.
30. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. Aaps Pharmsci 5(2):E10.
31. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14(8):969-975.
32. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. 2002. Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 13:109-133.
33. Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90(3):310-321.
34. Genovesi CS. 1983. Several uses for tangential-flow filtration in the pharmaceutical industry. J Parenter Sci Technol 37(3):81-86.
35. Shiloach J, Martin N, Moes H. 1988. Tangential flow filtration. Adv Biotechnol Processes 8:97-125.
36. van Reis R, Zydney A. 2001. Membrane separations in biotechnology. Curr Opin Biotechnol 12(2):208-211.
37. Thomas CR, Nienow AW, Dunnill P. 1979. Action of shear on enzymes: Studies with alcohol dehydrogenase. Biotechnol Bioeng 21(12):2263-2278.
38. Watterson JG, Schaub MC, Waser PG. 1974. Shear-induced protein-protein interaction at the air-water interface. Biochimica et Biophysica Acta 356(2):133-143.
39. Gehlert G, Luque S, Belfort G. 1998. Comparison of ultra- and microfiltration in the presence and absence of secondary flow with polysaccharides, proteins, and yeast suspensions. Biotechnol Progress 14(6):931-942.
40. Masters K. 1985. Spray drying handbook, 4th edn., New York: John Wiley & Sons.
41. Rouan SKE. 1996. Biotechnology-based pharmaceuticals. In: Banker GS, Rhodes CT, editors. Modern pharmaceutics, 3rd edn., New York: Marcel Dekker. p 843-873.
42. Poupitch G. 1994. Fluid bed drying in the laboratory. Am Biotechnol Lab 12(4):30-34.
43. Wildfong PL, Samy AS, Corfa J, Peck GE, Morris KR. 2002. Accelerated fluid bed drying using NIR monitoring and phenomenological modeling: Method assessment and formulation suitability. J Pharm Sci 91(3):631-639.
44. Mattern M, Winter G, Kohnert U, Lee G. 1999. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev Technol 4(2):199-208.
45. Miller DP, Anderson RE, de Pablo JJ. 1998. Stabilization of lactate dehydrogenase following freeze thawing and vacuum-drying in the presence of trehalose and borate. Pharm Res 15(8):1215-1221.
46. Avis KE. 1990. Parenteral preparations. In: Gennaro AR, editor Remington's pharmaceutical sciences, 18th edn., Easton, PA: Mack Publishing Company. p 1545-1569.
47. Harris LJ, Skaletsky E, McPherson A. 1995. Crystallization of intact monoclonal antibodies. Proteins 23(2):285-289.
48. Shenoy B, Wang Y, Shan W, Margolin AL. 2001. Stability of crystalline proteins. Biotechnol Bioeng 73(5):358-369.
49. Gatlin LA, Gatlin CAB. 1999. Formulation and administration techniques to minimize injection pain and tissue dammage associated with parenteral products. In: Gapta PK, Brazeau GA, editors. Injectable drug development: Techniques to reduce pain and irritation, 1st edn., Denver: Interpharm Press. p 401-421.
50. Jones AJS. 1993. Analytical methods for the assessment of protein formulations and delivery systems. In: Cleland JL, Langer R, editors. Formulation and delivery of peptides and proteins, 1st edn., Washington D.C.: American Chemical Society. p 22-45.
51. Pearlman R, Nguyen TH. 1990. Analysis of protein drugs. In: Lee VH, editor. Peptide and protein drug delivery, 1st edn., New York: Marcel Dekker, Inc. p 247-301.
52. Hatley RHM. 1990. International symposium on biological product freeze-drying and formulation, Bethesda MD. p 105-122.
53. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. 2001. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res 18(9):1345-1353.
54. McPhillips H, Craig DQ, Royall PG, Hill VL. 1999. Characterization of the glass transition of HPMC using modulated differential scanning calorimetry. Int J Pharm 180:83-90.
55. Costantino HR, Chen B, Griebenow K, Hsu CC, Shire SJ. 1998. Fourier-transform infrared spectroscopic investigation of the secondary structure of aqueous and dried recombinant human deoxyribonuclease I. Pharm Pharmacol Commun 4:391-395.
56. Prestrelski SJ, Tedeschi N, Arakawa T, Carpenter JF. 1993. Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophysical J 65(2):661-671.
57. Sharma VK, Kalonia DS. 2003. Steady-state trytophan fluorescence spectrscopy study to probe tertiary structure of proteins in solid powders. J Pharm Sci 92(4):890-899.
58. Shire SJ. 1992. Analytical ultracentrifugation and its use in biotechnology. In: Schuster TM, Laue TM, editors. Modern analytical ultracentrifugation, 1st edn., Boston: Birkhauser. p 261-297.
59. Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial review. Protein Sci 11(9):2067-2079.
60. Wen J, Arakawa T, Philo JS. 1996. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem 240(2):155-166.
61. Moore JM, Patapoff TW, Cromwell ME. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38(42):13960-13967.
62. Bloomfield VA. 1981. Quasi-elastic light scattering applications in biochemistry and biology. Annu Rev Biophys Bioeng 10:421-450.
63. Georgalis Y, Saenger W. 1999. Light scattering studies on supersaturated protein solutions. Sci Progress 82(Pt. 4):271-294.
64. Pecora R. 1972. Quasi-elastic light scattering from macromolecules. Annu Rev Biophys Bioeng 1:257-276.
65. Schurr JM. 1977. Dynamic light scattering of biopolymers and biocolloids. CRC Crit Rev Biochem 4(4):371-431.
66. Minton AP. 1989. Analytical centrifugation with preparative ultracentrifuges. Anal Biochem 176:209-216.
67. Johnson ML, Straume M. 1994. Comments on the analysis of sedimentation equilibrium experiments. In: Schuster TM, Laue TM, editors. Modern analytical ultracentrifugation, 1st edn., Boston: Birkhauser. p 37-63.
68. Schuck P. 1998. Sedimentation analysis of non-interacting and self-associating solutes using numerical solutions to the Lamm equation. Biophys J 75(3):1503-1512.
69. Schuck P, Perugini MA, Gonzales NR, Howlett GJ, Schubert D. 2002. Size-distribution analysis of proteins by analytical ultracentrifugation: Strategies and application to model systems. Biophys J 82(2):1096-1111.
70. de la Torre JG. 1992. Sedimentation coefficients of complex biological particles. In: Harding SE, Rowe AJ, Horton JC, editors. Analytical ultracentrifugation in biochemistry and polymer science, 1st edn., Cambridge, England: The Royal Society of Chemistry. p 333-345.
71. Liu J, Lester P, Builder S, Shire SJ. 1995. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34(33):10474-10482.